Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437086 · ClinicalTrials.gov registry record · Early Phase 1
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT00437086: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT00437086 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00437086, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the abnormal cells. PURPOSE: This clinical trial is studying the side effects and how well bortezomib works in treating patients with advanced myeloproliferative disorders.
Interventions
- DRUG PS-341
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437086
The ClinicalTrials.gov registry entry for NCT00437086 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PS-341 is the first listed.
NCT00437086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00437086 about?
NCT00437086 is a clinical study titled "Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders". RATIONALE: Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the abnormal cells. PURPOSE: This clinical trial is studying the side effects and how well bortezomib works in treating patients with advanced myeloprolif...
What is the current status of trial NCT00437086?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2005-09. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00437086?
The interventions under investigation include: PS-341 (DRUG).
Who is sponsoring clinical trial NCT00437086?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.